T0	Participants 362 581	Four hundred sixty-nine assessable advanced cancer patients were randomized to (1) oral megestrol acetate 800 mg/d liquid suspension plus placebo, (2) oral dronabinol 2.5 mg twice a day plus placebo, or (3) both agents.
T1	Participants 582 782	Eligible patients acknowledged that loss of appetite or weight was a problem and reported the loss of 5 pounds or more during 2 months and/or a daily intake of less than 20 calories/kg of body weight.
T2	Participants 912 946	megestrol acetate-treated patients
T3	Participants 1007 1035	dronabinol-treated patients:
T4	Participants 1435 1494	megestrol acetate-treated and combination-treated patients.
T5	Participants 1665 1700	men who received megestrol acetate.
T6	Participants 1813 1837	advanced cancer patients